Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20006667rdf:typepubmed:Citationlld:pubmed
pubmed-article:20006667lifeskim:mentionsumls-concept:C0376387lld:lifeskim
pubmed-article:20006667lifeskim:mentionsumls-concept:C0023911lld:lifeskim
pubmed-article:20006667lifeskim:mentionsumls-concept:C0021080lld:lifeskim
pubmed-article:20006667lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:20006667lifeskim:mentionsumls-concept:C0021079lld:lifeskim
pubmed-article:20006667lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:20006667pubmed:issue3lld:pubmed
pubmed-article:20006667pubmed:dateCreated2010-3-1lld:pubmed
pubmed-article:20006667pubmed:abstractTextHuman leukocyte antigen (HLA)-specific antibodies (Abs) were examined in 73 clinically stable liver transplant recipients divided into group A (n = 19; clinically tolerant), group B (n = 34; undergoing weaning, on minimal immunosuppression), and group C (n = 20; had failed drug withdrawal or weaning never attempted). Of 19 patients in group A, six (32%) had anti-HLA Abs; none were donor-specific. In contrast, 23 of 34 patients (67%) in group B and nine of 20 patients (45%) in group C exhibited anti-HLA Abs (p = 0.02). Furthermore, 15 of 19 patients in groups B and C (9/12, p = 0.01 and 6/7, p = 0.01, respectively) exhibited donor-specific anti-HLA Abs. The prevalence of donor-specific HLA Abs was significantly higher in nontolerant patients. Five years after initial evaluation, >90% (18/19) group A patients remained off immunosuppression. One of seven of these patients available for retesting exhibited donor-specific Abs. In group B, two-fourths of 34 patients (12%) weaned successfully were HLA-Ab negative; four patients who experienced rejection while undergoing weaning exhibited anti-HLA Ab initially and at 5 years. Thus, most of the liver recipients off immunosuppression lacked donor-specific alloAbs. The occurrence of these alloAbs should now be examined prospectively in a drug weaning trial.lld:pubmed
pubmed-article:20006667pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20006667pubmed:languageenglld:pubmed
pubmed-article:20006667pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20006667pubmed:citationSubsetIMlld:pubmed
pubmed-article:20006667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20006667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20006667pubmed:statusMEDLINElld:pubmed
pubmed-article:20006667pubmed:monthMarlld:pubmed
pubmed-article:20006667pubmed:issn1879-1166lld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:ThomsonAngus...lld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:ReyesJorgeJlld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:MazariegosGeo...lld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:ZeeviAdrianaAlld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:BentlejewskiC...lld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:CastellanetaA...lld:pubmed
pubmed-article:20006667pubmed:authorpubmed-author:GirnitaAlinAlld:pubmed
pubmed-article:20006667pubmed:copyrightInfo(c) 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:20006667pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20006667pubmed:volume71lld:pubmed
pubmed-article:20006667pubmed:ownerNLMlld:pubmed
pubmed-article:20006667pubmed:authorsCompleteYlld:pubmed
pubmed-article:20006667pubmed:pagination274-6lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:meshHeadingpubmed-meshheading:20006667...lld:pubmed
pubmed-article:20006667pubmed:year2010lld:pubmed
pubmed-article:20006667pubmed:articleTitleLiver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies.lld:pubmed
pubmed-article:20006667pubmed:affiliationThomas E. Starzl Transplantation Institute and Department of Pathology, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pennsylvania, USA.lld:pubmed
pubmed-article:20006667pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20006667pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20006667pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed